White Paper

Pipeline Analysis: Where Is Pharma Placing Its Bets?

Source: Life Science Leader

Kaiser Associates’ second annual Hot Indications List is a global analysis of 13,000+ pharma R&D programs and investment trends.  The report ranks top therapeutic areas and indications based on investment intensity, including clinical trials, VC funding, IPOs, and academic research.  The whitepaper also includes an analysis of the biggest “movers and losers” over the past year.

You can access it here: http://info.kaiserassociates.com/2016-hot-indications